Investor Relations

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

View all »   RSSRecent Releases

Apr 8, 2014
Merrimack Announces Preliminary Data From Pilot Diagnostic Imaging Study of MM-398

Mar 31, 2014
Merrimack to Present at the 2014 American Association for Cancer Research Annual Meeting

Stock Quote (NASDAQ: MACK)

Price:
5.00

Change:
- 0.08

Day High:
5.15

Day Low:
4.93

Volume:
175,900

10:28 AM ET on Apr 23, 2014
Delayed ~20 min. By eSignal.

Shareholder Tools